Clinical Burden of Symptomatic HEV‐3 Infection in Southern Spain Authors: María Casares‐Jimenez, Claudia Ferreira‐Tata, Isabel Viciana, Carolina Freyre‐Carrillo, Pedro Lopez‐Lopez, Ana Belen Perez, Berta Becerril‐Carral, Ana Fuentes, Juan Macías, Lucia Rios‐Muñoz, Francisco Franco‐Alvarez de Luna, María Teresa Cabezas‐Fernandez, Diana Corona‐Mata, Antonio Rivero‐Juarez, Antonio Rivero Published: 2026 ABSTRACT ABSTRACTBackgroundHepatitis E virus genotype 3 (HEV‐3) is a major cause of acute hepatitis in Europe. However, the clinical burden of symptomatic infection in routine practice and the relative contribution of host and viral factors to disease severity remain incompletely defined. We aimed to characterise the clinical burden, molecular epidemiology and determinants of adverse outcomes in patients with symptomatic HEV‐3 infection.MethodsProspective multicentre study including patients with suspected HEV infection from ten hospitals in southern Spain between 2022 and 2025. Samples were analysed at a central laboratory using a standardised diagnostic algorithm based on HEV IgM and HEV RNA testing, with molecular characterisation of viraemic cases. Demographic, clinical and outcome data were extracted from medical records. Multivariable logistic regression analyses were performed to identify factors associated with hospital admission and severe acute hepatitis.ResultsAmong 1124 tested patients, 267 HEV infections were diagnosed (23.7%). Overall diagnostic positivity remained consistently high throughout the study period. Of the 267 patients, 111 (41.6%) required hospital admission, 14 (5.2%) developed severe acute hepatitis and three died (overall mortality 1.1%), all of whom had major comorbidities. Major comorbidity was independently associated with hospital admission and severe acute hepatitis, whereas HEV‐3 clade was not.ConclusionSymptomatic HEV‐3 infection in southern Spain was associated with a substantial clinical burden. Adverse outcomes were driven primarily by host comorbidity rather than by the viral features assessed in this cohort, while molecular surveillance provided useful epidemiological context on circulating strains.Keywords: clinical burden, hepatitis E virus, hospitalisation, molecular epidemiology, symptomatic infection Introduction Hepatitis E virus (HEV) is a major cause of acute hepatitis in Europe [1], with most autochthonous infections caused by zoonotic genotype 3 (HEV‐3) [2]. Although many HEV‐3 infections are asymptomatic or self‐limited, symptomatic infection may lead to hospital admission, severe acute hepatitis and death, particularly in vulnerable patients [3, 4]. This clinical heterogeneity has increased interest in the determinants of disease severity. Current evidence indicates that adverse outcomes in HEV‐3 infection are largely driven by host‐related factors, particularly older age and major underlying comorbidities [5]. At the same time, viral factors have also been proposed as contributors to clinical heterogeneity. In particular, several studies suggest that clade I infections, especially subtype 3f, may be associated with more severe biochemical or clinical presentation than clade II infections [6, 7]. However, the relative contribution of host vulnerability and viral diversity remains insufficiently defined in real‐world clinical cohorts. Most available evidence comes either from hospital‐based series with limited molecular characterisation or from laboratory surveillance systems with sparse and heterogeneous clinical information, and many studies are cross‐sectional in design. This gap is particularly relevant in southern Spain, where HEV‐3f circulation is well established [8] and where hospital‐based data suggest a substantial burden of clinically significant hepatitis E, including cases of acute liver failure or acute‐on‐chronic liver failure and non‐negligible in‐hospital mortality [9]. Yet these datasets rarely combine detailed clinical phenotyping, comorbidity assessment, outcome evaluation and robust HEV‐3 typing within the same population and time frame. Longitudinal studies integrating standardised clinical and molecular data are therefore needed to define the clinical burden of symptomatic HEV‐3 infection and clarify whether subtype distribution adds information beyond host‐related risk factors. Southern Spain provides a particularly informative setting for this question, given the predominance of HEV‐3f and the opportunity to examine the clinical expression of infection in a clade I‐dominated context. We therefore conducted a prospective multicentre study in southern Spain integrating standardised clinical data and HEV‐3 molecular characterisation in patients with symptomatic infection. We aimed to define the clinical burden of symptomatic HEV‐3 infection, describe clade distribution over time, and assess the relative contribution of host and viral factors to hospital admission, severe acute hepatitis and death. Methods Study Design This was a prospective multicentre study conducted in Andalusia, southern Spain, between 2022 and 2025, including patients with suspected acute HEV infection evaluated at ten reference hospitals of the Andalusian Health System. These centres, located across seven provinces, provide specialist care to an estimated population of approximately 4 million inhabitants. Suspected HEV infection was defined as acute hepatitis with compatible clinical and/or biochemical features, ALT ≥ 3 times the upper limit of normal, and negative screening for other hepatotropic or relevant systemic viral infections at the referring hospital (HAV, HBV, HCV, EBV and CMV). Serum samples were sent through the routine transport system to a central laboratory at IMIBIC and processed within 24 h or stored at −80°C until testing. HEV Testing and Molecular Analysis Confirmed HEV infection was defined as detectable HEV RNA and/or confirmed HEV IgM positivity. HEV IgM antibodies were assessed using a commercial line immunoassay (recomLine HEV IgG/IgM, Mikrogen, Germany). HEV RNA was tested in all samples using a previously described molecular algorithm [10, 11]. In patients considered at risk of chronic infection, follow‐up HEV RNA testing at ≥ 3 months was performed, defining persistent viraemia beyond 3 months as chronic hepatitis E. For HEV RNA‐positive samples, partial ORF2 sequences (450 nt) were generated following the HEVnet consensus protocol [12]. Sequences were assigned to subtype and, when required, to clade by phylogenetic analysis. HEV‐3 clades were defined as clade I (subtypes 3e, 3f and 3 g) and clade II (subtypes 3a, 3b, 3c, 3 h, 3i, 3j and 3 m). Data Collection Demographic, clinical and laboratory data were prospectively recorded in a REDCap database. Variables included demographic characteristics; complete blood count (leukocytes, neutrophils, haemoglobin and platelets); liver function tests; coagulation parameters; clinical presentation; hospital admission; all‐cause mortality during the index episode; and underlying comorbidities. Clinical records were independently reviewed by two physicians, who adjudicated disease severity. Severe acute hepatitis was defined as ALT ≥ 10 times the upper limit of normal together with impaired liver function, including increased international normalised ratio (INR) and/or hepatic encephalopathy. Acute‐on‐chronic liver failure (ACLF) was defined as acute hepatic decompensation in a patient with underlying chronic liver disease. Statistical Analysis Analyses were restricted to patients with confirmed HEV infection. Categorical variables were summarised as counts and percentages, and continuous variables as median and interquartile range. Annual HEV positivity was calculated as the proportion of confirmed infections among tested patients by calendar year, with exact 95% confidence intervals (95% CIs). Comparisons between groups were performed using the chi‐square or Fisher's exact test for categorical variables and the Mann–Whitney U test for continuous variables. Multivariable logistic regression models were fitted to identify factors associated with hospital admission. Model 1 included the full cohort, whereas Model 2 was restricted to patients with available HEV‐3 sequence data in order to assess the association between viral clade and hospital admission. A separate multivariable logistic regression model was fitted to explore factors associated with severe acute hepatitis. Adjusted odds ratios (aORs) and 95% CIs were calculated. A two‐sided p value < 0.05 was considered statistically significant. Analyses were performed using IBM SPSS Statistics version 16. Ethics Statement This study was designed and conducted in accordance with the Declaration of Helsinki and applicable Spanish legislation guidelines (RD 8/2003). The Ethics and Clinical Trials Committee (CEIC) of Andalusia (Spain) approved the study protocol. Results Study Population and HEV Positivity During the study period, 1124 patients with suspected acute HEV infection were tested at the central laboratory, of whom 267 were diagnosed with HEV infection, corresponding to an overall positivity of 23.7% (95% CI 21.3%–26.3%). Among these cases, HEV IgM was positive in 231 cases (86.5%) and HEV RNA was detected in 166 (62.2%). Thirty‐six of the 267 patients (13.5%) were HEV RNA‐positive but HEV IgM‐negative. Sequencing was successful in 129 of 166 HEV RNA‐positive cases (77.7%). Genotype 3f predominated (107/129; 82.9%), with only sporadic detection of other subtypes. Overall, 116 infections (89.9%) belonged to clade I and 13 (10.1%) to clade II. Clinical Characteristics and Outcomes Among patients with HEV infection, 175 (65.5%) were men and 92 (34.5%) women, with a median age of 62 years (51–75). The most frequent clinical manifestations were jaundice (39.0%; n = 104), gastrointestinal symptoms (35.6%; n = 95), and fever (24.3%; n = 65). Extrahepatic manifestations were observed in 14 patients (5.2%), including Guillain‐Barré syndrome in two. The median ALT level was 296 IU/L (160–995), and 89 (33.3%) had ≥ 10 times the upper limit of normal. Seventy‐eight patients (29.2%) had at least one major comorbidity, most commonly chronic liver disease (9.0%) and active malignancy (7.5%). A total of 111 patients (41.6%) required hospital admission, of whom 14 (5.2% of the overall cohort) met criteria for severe acute hepatitis. Three hospitalised patients died, corresponding to an overall mortality rate of 1.1% (95% CI 0.23%–3.2%) and 4.5% (95% CI 0.9%–7.1%) among admitted individuals. Two patients died from fulminant hepatic failure, one with metastatic breast cancer and the other with chronic kidney disease as major comorbidities. The third death occurred in a patient with alcohol‐related cirrhosis who developed ACLF. In 24 patients with detectable HEV RNA, follow‐up viral load testing was requested at 3 months or later. This group included three patients with HIV infection, 11 with major autoimmune disorders, and 10 additional patients with major comorbidities but no known immunosuppression. In none of these cases was HEV RNA still detectable at 3 months, and all were classified as having self‐limited infection. Factors Associated With Admission and Severity The analysis of factors associated with hospital admission is summarised in Table 1. Admitted patients had higher ALT levels, were more likely to present ALT ≥ 10 times the upper limit of normal and had lower albumin concentrations compared with outpatients. Digestive symptoms and jaundice were significantly more frequent among hospitalised patients, whereas fever occurred at similar rates in both groups. The presence of at least one major comorbidity was strongly associated with admission (48.2% vs. 15.5%, p < 0.001), particularly chronic liver disease, active malignancy, metabolic syndrome and major cardiovascular disease. In contrast, microbiological characteristics, including HEV RNA levels, subtype distribution and clade (I vs. II), as well as year of diagnosis were not associated with hospital admission. Multivariable logistic regression models for hospital admission are shown in Table 2. In the full cohort, major comorbidity and ALT ≥ 10× the upper limit of normal remained independently associated with hospital admission, whereas age and gender did not. In the subset of sequenced cases, these associations persisted, and no association was observed between HEV‐3 clade and hospital admission. TABLE 1Clinical, analytical and virological characteristics of patients with acute HEV infection according to hospital admission.VariableHospital admission (n = 111)Non‐admission (n = 156) p Age (years)64.5 (53–75)60 (49–75)0.304Gender male80 (71.4)87 (60)0.065ALT (IU/mL)555 (151–1427)360 (135–660)< 0.001ALT level x10 UNL57 (50.9)32 (20.6)< 0.001Albumin (g/dL)3.5 (2.8–3.8)4.1 (3.6–4.3)< 0.001Bilirubin (mg/dL)5.1 (1.3–10)1.05 (0.53–2.65)< 0.001Clinical symptomsDigestive60 (53.6)35 (22.6)< 0.001Fever32 (28.6)33 (21.3)0.194Jaundice76 (67.9)28 (18.1)< 0.001Extrahepatic manifestations3 (2.7)1 (0.6)0.005Major comorbidity54 (48.2)24 (15.5)< 0.001Type of major comorbidityChronic liver disease18 (16.1)8 (5.2)0.006Active malignancy13 (11.6)6 (3.9)0.027Autoimmune and immune‐mediated disorder7 (6.3)4 (2.6)0.211Chronic renal dysfunction5 (4.5)1 (0.6)0.085Metabolic syndrome7 (6.3)2 (1.3)0.038Major cardiovascular disease4 (3.6)00.03HIV03 (2.1)0.17HEV‐3 viral load (logUI/mL)5.3 (4.3–5.8)4.9 (3.5–5.6)0.18HEV‐3 subtype0.4213a01 (1.6)3c2 (3.1)3 (4.6)3e1 (1.8)3 (4.6)3f55 (85.9)52 (80)3 m3 (4.6)3 (4.6)3na3 (4.6)3 (4.6)HEV‐3 genotype cladeClade I58 (90.6)58 (89.2)0.89Clade II6 (9.4)7 (10.8) Note: Data are expressed as medians (Q1‐Q3) or number of patients (percentage), as appropriate. Major comorbidity includes chronic liver disease, active malignancy, chronic kidney disease, metabolic syndrome, major cardiovascular disease, autoimmune and immune‐mediated disorders and HIV infection. Major cardiovascular disease comprises ischaemic heart disease and atrial fibrillation on anticoagulation; chronic liver disease includes chronic hepatitis B and alcohol‐related liver disease; autoimmune and immune‐mediated disorders include multiple sclerosis, autoimmune thyroiditis, inflammatory bowel disease and other systemic immune‐mediated conditions. HEV‐3 genotype clades were determined in patients with available sequence data. 3na means not assigned genotype. Clinical, analytical and virological characteristics of patients with acute HEV infection according to hospital admission. Note: Data are expressed as medians (Q1‐Q3) or number of patients (percentage), as appropriate. Major comorbidity includes chronic liver disease, active malignancy, chronic kidney disease, metabolic syndrome, major cardiovascular disease, autoimmune and immune‐mediated disorders and HIV infection. Major cardiovascular disease comprises ischaemic heart disease and atrial fibrillation on anticoagulation; chronic liver disease includes chronic hepatitis B and alcohol‐related liver disease; autoimmune and immune‐mediated disorders include multiple sclerosis, autoimmune thyroiditis, inflammatory bowel disease and other systemic immune‐mediated conditions. HEV‐3 genotype clades were determined in patients with available sequence data. 3na means not assigned genotype. TABLE 2Multivariable logistic regression analysis of factors associated with hospital admission among patients with symptomatic HEV infection.VariableCategoryaOR (95%) p Model IGenderMale10.067Female0.57 (0.31–1.04)Major comorbidityNo1< 0.001Yes3.2 (1.73–5.9)ALT level x10 UNLNo10.005Yes2.31 (1.28–4.18)Ageyears1.007 (0.99–1.024)0.404Model IIMajor comorbidityNo10.014Yes2.67 (1.2–5.8)ALT level x10 UNLNo10.006Yes2.86 (1.36–6.01)HEV‐3 cladeClade I1.09 (0.32–3.71)0.892Clade II1 Note: Model 1 included the full cohort of patients with symptomatic HEV infection (n = 267). Model 2 was restricted to patients with available HEV‐3 sequence data (n = 128) in order to assess the association between viral clade and hospital admission. Adjusted Odds ratios (aORs) and 95% confidence intervals (95% CIs) were estimated using multivariable logistic regression. Age was analysed as a continuous variable (per year). ALT was categorised as > 10× the upper limit of normal (ULN). Major comorbidity was defined according to the clinical classification used in the study cohort. Clade II was used as the reference category for HEV‐3 clade comparisons. Multivariable logistic regression analysis of factors associated with hospital admission among patients with symptomatic HEV infection. Note: Model 1 included the full cohort of patients with symptomatic HEV infection (n = 267). Model 2 was restricted to patients with available HEV‐3 sequence data (n = 128) in order to assess the association between viral clade and hospital admission. Adjusted Odds ratios (aORs) and 95% confidence intervals (95% CIs) were estimated using multivariable logistic regression. Age was analysed as a continuous variable (per year). ALT was categorised as > 10× the upper limit of normal (ULN). Major comorbidity was defined according to the clinical classification used in the study cohort. Clade II was used as the reference category for HEV‐3 clade comparisons. Patients who developed severe acute hepatitis were more likely to have at least one major comorbidity than those without severe disease (64.3% vs. 27.4%, p = 0.006) (Table 3). In multivariable analysis performed in the subset with available sequence and complete clinical data (n = 128), major comorbidity remained the only factor associated with severe acute hepatitis (aOR 6.02, 95% CI 1.13–32.0; p = 0.035), whereas age, sex and HEV‐3 clade were not associated with this outcome. TABLE 3Clinical and virological factors associated with severe acute hepatitis.VariableSevere acute hepatitis (n = 14)No severe acute hepatitis (n = 253) p aOR (95% CI) p Age (years)68.5 (52–76.2)61 (51–75)0.5371.009 (0.98–1.06)0.747Gender male11 (78.6)156 (64.5)0.3911.029 (0.18–5.73)0.94Major comorbidity9 (64.3)69 (27.4)0.0066.024 (1.13–32)0.035HEV‐3 genotype cladeClade I7 (87.5)109 (90.1)0.5830.505 (0.049–5.17)0.56Clade II1 (12.5)12 (9.9)1 Note: Continuous variables are presented as median (interquartile range, IQR) and categorical variables as number (%). Univariable comparisons were performed using the Mann–Whitney U test, chi‐square test or Fisher's exact test, as appropriate. Adjusted odds ratios (aORs) and 95% confidence intervals (95% CIs) were estimated using multivariable logistic regression in the subset of patients with available HEV‐3 sequence data and complete clinical data (n = 128). Age was analysed as a continuous variable (per year). Clade II was used as the reference category for HEV‐3 clade comparisons. Clinical and virological factors associated with severe acute hepatitis. Note: Continuous variables are presented as median (interquartile range, IQR) and categorical variables as number (%). Univariable comparisons were performed using the Mann–Whitney U test, chi‐square test or Fisher's exact test, as appropriate. Adjusted odds ratios (aORs) and 95% confidence intervals (95% CIs) were estimated using multivariable logistic regression in the subset of patients with available HEV‐3 sequence data and complete clinical data (n = 128). Age was analysed as a continuous variable (per year). Clade II was used as the reference category for HEV‐3 clade comparisons. Temporal Changes in Positivity, Molecular Distribution and Outcomes Temporal patterns of HEV positivity, clinical severity and clade distribution are summarised in Table 4. Of the 1124 patients tested during the study period, 312 (27.8%) were evaluated in 2022, 193 (17.2%) in 2023, 362 (32.2%) in 2024 and 257 (22.9%) in 2025. Annual diagnostic positivity ranged from 16.0% in 2022 to 31.1% in 2025. The proportion of patients requiring hospital admission remained relatively stable over time, ranging from 39.6% to 48.0%, and the frequency of severe acute hepatitis varied between 3.4% and 10.6% without a consistent temporal pattern. Deaths were infrequent in all calendar years (0%–2.1%), and the proportion of patients with major comorbidities showed a slight decline over the study period. Subtype 3f remained predominant throughout, consistently accounting for the large majority of sequenced cases each year. Clade II infections were detected mainly from 2024 onwards and remained a minority of cases. TABLE 4Temporal trends in clinical outcomes, comorbidity and HEV‐3 clade/subtype distribution among patients with acute HEV infection, 2022–2025.Variable2022 (n = 50)2023 (n = 48)2024 (n = 89)2025 (n = 80) p Hospital admission24 (48)19 (39.6)36 (40.4)33 (41.3)0.81Severe acute hepatitis3 (6)5 (10.6)3 (3.4)3 (3.8)0.28Deaths1 (2)1 (2.1)1 (1.1)00.64Comorbidity19 (38)16 (33)25 (28.1)18 (22.5)0.255HEV cladeClade I26 (92.9)26 (100)34 (85)30 (85.7)0.177Clade II2 (7.1)06 (15)5 (14.3)HEV‐3 subtype0.7963f23 (82.1)24 (92.3)32 (80)28 (80)3e2 (7.1)1 (3.8)01 (2.9)3c1 (3.6)02 (5)2 (5.7)3 m1 (3.6)03 (7.5)2 (5.7)3a0001 (2.9)3na1 (3.6)1 (3.8)3 (7.5)1 (2.9) Note: Data are shown as absolute numbers and percentages for each calendar year. Hospital admission, severe acute hepatitis and deaths refer to clinical outcomes at initial presentation or during the index episode. Major comorbidity includes chronic liver disease, active malignancy, chronic kidney disease, metabolic syndrome, major cardiovascular disease, autoimmune or immune‐mediated disorders and HIV infection. HEV clades and genotypes are reported for patients in whom HEV‐3 sequencing was available; percentages in brackets correspond to the proportion within each year. 3na means not assigned genotype. Temporal trends in clinical outcomes, comorbidity and HEV‐3 clade/subtype distribution among patients with acute HEV infection, 2022–2025. Note: Data are shown as absolute numbers and percentages for each calendar year. Hospital admission, severe acute hepatitis and deaths refer to clinical outcomes at initial presentation or during the index episode. Major comorbidity includes chronic liver disease, active malignancy, chronic kidney disease, metabolic syndrome, major cardiovascular disease, autoimmune or immune‐mediated disorders and HIV infection. HEV clades and genotypes are reported for patients in whom HEV‐3 sequencing was available; percentages in brackets correspond to the proportion within each year. 3na means not assigned genotype. Discussion In our setting, HEV‐3 was a frequent cause of clinically suspected acute hepatitis and was associated with a substantial burden of hospitalisation and severe disease, particularly among older adults with relevant comorbidities. Approximately two in five confirmed cases required hospital admission, and severe acute hepatitis occurred in approximately 1 in 20 patients. Although deaths were uncommon overall, the case‐fatality rate among hospitalised patients approached 5%, and all fatal cases occurred in patients with major underlying comorbidity. These findings add to growing evidence that hepatitis E is not uniformly mild in routine clinical practice and support systematic inclusion of HEV in the differential diagnosis of acute hepatitis and in routine diagnostic algorithms [3]. The multivariable analyses indicate that adverse clinical outcomes were primarily associated with host vulnerability rather than with the viral features evaluated in this cohort. Major comorbidity was independently associated with hospital admission and was the only variable associated with severe acute hepatitis in adjusted analyses, whereas age and sex were not. ALT ≥ 10 × ULN was also independently associated with hospital admission, likely reflecting a more severe biochemical presentation at diagnosis. These findings are consistent with previous reports identifying cirrhosis [5, 9] and immunosuppression as determinants of poor outcome, supporting initial risk stratification based on underlying clinical vulnerability [13, 14]. In addition to host‐related factors, the potential contribution of viral characteristics to disease severity warrants careful consideration. Previous studies from Germany, Belgium and France have reported an association between clade I (subtypes 3e/3f/3 g) infections and more severe clinical presentations, including higher bilirubin levels and increased rates of hospitalisation and mortality [6, 7, 15, 16]. In our cohort, however, no association was observed between HEV‐3 clade and either hospital admission or severe acute hepatitis. This negative finding should be interpreted cautiously, as our molecular dataset was dominated by subtype 3f and included only a small number of clade II infections, which limited the precision of comparisons between variants. A similar limitation was reported in Italy, where a cohort also dominated by subtype 3f did not show a clear relationship between subtype and severity [17]. In this context, molecular characterisation provided robust epidemiological information on circulating strains but did not add clear prognostic discrimination beyond host‐related factors. From a diagnostic microbiology perspective, our findings reinforce a practical message. In our study, a relevant proportion of confirmed cases would not have been identified by serology alone, as a substantial subset of viraemic patients lacked detectable HEV IgM at diagnosis. This observation is consistent with previous studies from our diagnostic network showing the limited value of single‐sample IgM testing for acute hepatitis E and supporting the routine combination of serological and molecular assays in clinically suspected cases [11, 18]. This is consistent with external data showing that reliance on anti‐HEV IgM alone may miss acute infections and limit molecular characterisation of circulating strains [19]. Diagnostic algorithms based exclusively on serology are therefore likely to underestimate clinically relevant HEV infection and limit downstream virological analysis. This is particularly relevant in our regional ecological context. The region combines intensive pig farming, high levels of pork and game consumption, and a substantial wild‐boar reservoir, all recognised contributors to HEV‐3 transmission in Europe. The sustained predominance of subtype 3f in our cohort is coherent with previous data from southern Spain showing circulation of this subtype in pigs [20, 21], wild boar [22], pork products [23] and environmental samples [24]. The detection of a small number of clade II strains, mainly in the later years of the study, also suggests that the regional molecular landscape may be becoming more diverse. Thus, molecular diagnostic strategies enabling both case detection and strain characterisation are especially valuable, as they provide a framework for linking clinical surveillance with animal and environmental data. These observations support integration of clinical and molecular data within a broader One Health framework [25]. This study has several limitations. First, although the surveillance network included ten reference hospitals, it does not cover all centres in the region and may therefore underestimate the true burden of HEV infection. Second, while our system integrates clinical and molecular data in humans, it does not include systematic animal or environmental surveillance, which limits our ability to link human infections directly to specific reservoirs. Third, as testing was based on clinical suspicion, milder or asymptomatic infections may have been under‐represented, and our findings therefore primarily reflect clinically apparent disease. Finally, the small number of clade II strains and severe clinical events reduces the precision of analyses exploring the contribution of viral diversity to outcome. In conclusion, symptomatic HEV‐3 infection in southern Spain carried a substantial clinical burden, with hospital admission and severe acute hepatitis concentrated in patients with major comorbidities. Host vulnerability emerged as the main determinant of adverse outcome in this cohort, whereas molecular characterisation showed sustained predominance of subtype 3f without a clear association between viral clade and severity. These findings support the value of prospective clinical and molecular surveillance to define the burden and regional molecular epidemiology of hepatitis E in routine practice. Author Contributions Isabel Viciana: investigation, writing – review and editing, validation, supervision, resources. Diana Corona‐Mata: data curation, supervision, resources, project administration, validation, visualization, investigation, writing – review and editing. Antonio Rivero‐Juarez: conceptualization, investigation, funding acquisition, writing – original draft, writing – review and editing, visualization, validation, methodology, software, formal analysis, project administration, resources, supervision, data curation. Pedro Lopez‐Lopez: investigation, methodology, visualization, data curation, software, formal analysis, writing – review and editing. Antonio Rivero: conceptualization, funding acquisition, writing – review and editing, validation, resources, supervision, data curation, visualization, investigation. Carolina Freyre‐Carrillo: investigation, validation, writing – review and editing, supervision, resources. María Casares‐Jimenez: conceptualization, investigation, writing – original draft, methodology, validation, writing – review and editing, software, data curation, project administration. Claudia Ferreira‐Tata: conceptualization, investigation, writing – original draft, methodology, visualization, writing – review and editing, project administration, data curation. Ana Belen Perez: investigation, validation, writing – review and editing, resources, supervision, visualization. María Teresa Cabezas‐Fernandez: validation, investigation, writing – review and editing, supervision, resources. Ana Fuentes: investigation, writing – review and editing, supervision, resources, validation. Berta Becerril‐Carral: investigation, validation, writing – review and editing, supervision, resources. Juan Macías: investigation, resources, supervision, writing – review and editing, validation. Lucia Rios‐Muñoz: data curation, software, project administration, resources, investigation, visualization, methodology, writing – review and editing. Francisco Franco‐Alvarez de Luna: investigation, writing – review and editing, resources, supervision, validation. Funding This work was supported by the Andalusian General Secretariat for Research, Development, and Innovation in Health (PI‐0287‐2019), the Spanish Ministry of Health (RD12/0017/0012), the European Regional Development Fund (ERDF), and the Carlos III Health Institute (Research Project grant numbers: PI16/01297, PI19/00864, PI21/00793 and PI22/01098). Projects “PI21/00793” and “PI22/01098” were funded by the Carlos III Health Institute (ISCIII) and co‐funded by the European Union. The work is also supported by the CIBERINFEC (CB21/13/00083, CB21/13/00118 and CB21/13/00088), Carlos III Health Institute, Spanish Ministry of Science and Next Generation EU. ARJ is supported by a contract from the Spanish Junta de Andalucía (Nicolas Monardes program: C1‐0001‐2023). Maria Casares‐Jimenez and Lucia Rios‐Muñoz are recipients of a CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD (PFIS) (FI22/00180 and FI25/00103) from the Instituto de Salud Carlos III (ISCIII) and co‐funded by the European Union. Claudia Ferreira is recipient of a Rio‐Hortega (CM24/00099) grant from the Instituto de Salud Carlos III (ISCIII) and co‐funded by the European Union. Diana Corona‐Mata is the recipient of a Juan Rodes (JR24/00047) grant from the Instituto de Salud Carlos III (ISCIII) and co‐funded by the European Union. Pedro Lopez‐Lopez is the recipient of a Sara Borrell (CD24/00007) grant from the Instituto de Salud Carlos III (ISCIII) and co‐funded by the European Union. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgements The authors would like to thank Ismael Zafra Soto, Laura Ruiz Torres, and Gema Delgado for their technical support throughout the study period. Funding for open access charge: Universidad de Cordoba/CBUA. Casares‐Jimenez M., Ferreira‐Tata C., Viciana I., et al., “Clinical Burden of Symptomatic HEV‐3 Infection in Southern Spain,” Alimentary Pharmacology & Therapeutics 64, no. 6 (2026): 792–799, 10.1111/apt.70790. Handling Editor: Geoffrey Dusheiko Data Availability Statement All the data generated or analyzed during the study are included in this published article. The datasets used and/or analyzed during the present research project are available from the corresponding author upon reasonable request. The sequences used in the present study are publicly available in GenBank under the accession numbers: MN628557 to MN628567, MT250081 to MT250083, MN537838, MN914126, MN914127, MT776550 to MT776554, MT854329, MW143072, OM236461 to OM236465, MZ964415, MZ964416, OL741633 to OL741655, ON720840 to ON720847, ON921072 to ON921078, OP793784 to OP793790, and PX988354 to PX988486. References Associated Data Data Availability Statement All the data generated or analyzed during the study are included in this published article. The datasets used and/or analyzed during the present research project are available from the corresponding author upon reasonable request. The sequences used in the present study are publicly available in GenBank under the accession numbers: MN628557 to MN628567, MT250081 to MT250083, MN537838, MN914126, MN914127, MT776550 to MT776554, MT854329, MW143072, OM236461 to OM236465, MZ964415, MZ964416, OL741633 to OL741655, ON720840 to ON720847, ON921072 to ON921078, OP793784 to OP793790, and PX988354 to PX988486.